RFK Jr pushes for FDA approval of BPC 157 peptide Eric Topol, MD posted on the topic LinkedIn FDA Moves on Peptides: What Compounding Pharmacies Need to Know FDA issued its first warning letter to a dispenser (a medical spa) for violating the Drug Supply Chain Security Act (DSCSA), including failing to source products from authorized trading partners and The FDA scheduled a hearing on peptides and the implications could be significant for prescribers and clinics. With BPC 157, TB 500, and others under 503A review, questions around compounding, compliance, and what is FDA Peptide Update: Category 2 Removals Explained